Amy K O'Sullivan

Summary

Affiliation: Health Economics and Outcomes

Publications

  1. doi Cost estimation of cardiovascular disease events in the US
    Amy K O'Sullivan
    i3 Innovus, Medford, Massachusetts, USA
    Pharmacoeconomics 29:693-704. 2011
  2. pmc Cost-effectiveness of magnetic resonance guided focused ultrasound for the treatment of uterine fibroids
    Amy K O'Sullivan
    i3 Innovus
    Int J Technol Assess Health Care 25:14-25. 2009
  3. doi Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States
    Amy K O'Sullivan
    i3 Innovus, Medford, MA, USA
    Value Health 12:666-73. 2009
  4. ncbi Health care utilization & costs for cystic fibrosis patients with pulmonary infections
    Amy K O'Sullivan
    i3 Innovus, Medford, MA 02155, USA
    Manag Care 20:37-44. 2011
  5. doi Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease
    Amy K O'Sullivan
    Global Health Economics Research, i3 Innovus, Medford, MA, USA
    Am J Health Syst Pharm 69:149-56. 2012
  6. doi Cost effectiveness of targeted high-dose atorvastatin therapy following genotype testing in patients with acute coronary syndrome
    Anju Parthan
    OptumInsight, One Main Street, Suite 1040, Cambridge, MA 02142, USA
    Pharmacoeconomics 31:519-31. 2013
  7. ncbi Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations?
    Amy K O'Sullivan
    Innovus Research US Inc, Medford, MA, USA
    Value Health 8:67-79. 2005

Collaborators

Detail Information

Publications7

  1. doi Cost estimation of cardiovascular disease events in the US
    Amy K O'Sullivan
    i3 Innovus, Medford, Massachusetts, USA
    Pharmacoeconomics 29:693-704. 2011
    ..In this study, we developed cost prediction equations that facilitate estimation of the costs of various cardiovascular events for patients of specific demographic and clinical characteristics over varying time horizons...
  2. pmc Cost-effectiveness of magnetic resonance guided focused ultrasound for the treatment of uterine fibroids
    Amy K O'Sullivan
    i3 Innovus
    Int J Technol Assess Health Care 25:14-25. 2009
    ..The aim of this study is to evaluate the cost-effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) compared with alternative treatments for uterine fibroids in the United States...
  3. doi Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States
    Amy K O'Sullivan
    i3 Innovus, Medford, MA, USA
    Value Health 12:666-73. 2009
    ..Our objective was to assess the cost-effectiveness of posaconazole versus FLU or ITRA for prevention of IFIs among neutropenic patients...
  4. ncbi Health care utilization & costs for cystic fibrosis patients with pulmonary infections
    Amy K O'Sullivan
    i3 Innovus, Medford, MA 02155, USA
    Manag Care 20:37-44. 2011
    ..To examine patterns of health care utilization and costs among cystic fibrosis (CF) patients with pulmonary infections...
  5. doi Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease
    Amy K O'Sullivan
    Global Health Economics Research, i3 Innovus, Medford, MA, USA
    Am J Health Syst Pharm 69:149-56. 2012
    ..The results of a pharmacoeconomic study of the cost-effectiveness of posaconazole versus fluconazole in preventing invasive fungal infections (IFIs) in patients with graft-versus-host disease (GVHD) are reported...
  6. doi Cost effectiveness of targeted high-dose atorvastatin therapy following genotype testing in patients with acute coronary syndrome
    Anju Parthan
    OptumInsight, One Main Street, Suite 1040, Cambridge, MA 02142, USA
    Pharmacoeconomics 31:519-31. 2013
    ..We assessed the cost effectiveness of testing for the KIF6 variant followed by targeted statin therapy (KIF6 Testing) versus not testing patients (No Test) and treating them with P40 or A80 in the USA from a payer perspective...
  7. ncbi Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations?
    Amy K O'Sullivan
    Innovus Research US Inc, Medford, MA, USA
    Value Health 8:67-79. 2005
    ..The objective of this article is to discuss issues surrounding the conduct of "piggyback evaluations," in which health-economic data are collected within an otherwise typical clinical trial...